Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
To accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
Use the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
Human leukocyte antigens A2 (HLA-A2), also known as HLA-A*02, is a human leukocyte antigen serotype within the HLA-A serotype group. The serotype is determined by the antibody recognition of the α2 domain of the HLA-A α-chain. For A*02, the α chain is encoded by the HLA-A*02 gene and the β chain is encoded by the B2M locus. In human melanoma, the expression of HLA-A2 antigen in human melanoma expression is related to tumor cell recognition by autologous T Iymphocytes. Furthermore, HLA-A2 appears to be somewhat less effective than other HLA-As at protecting against HIV infections. HLA-A2 is linked with decreased risk of developing Epstein-Barr virus (EBV)-positive Hodgkin lymphoma(HL).
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.